context therapeutics published in stat report on new cancer targets
Published 1 year ago • 1.2K plays • Length 4:28Download video MP4
Download video MP3
Similar videos
-
5:33
context therapeutics announces bispecific antibody clinical candidate to treat cldn6 cancers
-
6:25
context therapeutics shares #asco23 data on cldn-6 targeted treatments and ctim-76 update
-
5:49
context therapeutics releases ctim-76 claudin 6 therapeutic antibody updates
-
6:11
context therapeutics reveals preclinical data from two pipeline programs
-
5:11
context therapeutics says its ona-xr therapy shows positive data in early breast cancer
-
1:01:14
context therapeutics webinar: identification of ctim-76, a cldn6xcd3 bi-specific antibody
-
32:44
context therapeutics webinar: claudin 6 x cd3 bispecific antibody data update
-
4:51
context therapeutics announces positive responses in phase 2 oath clinical trial
-
10:11
context therapeutics - forging better lives : seeking radical change for cancers
-
4:44
context therapeutics ceo marty lehr notes progress towards the clinic with ctim-76 in 2q update
-
4:29
context therapeutics releases corporate priorities and pipeline milestones for 2023
-
4:44
context therapeutics ctim-76 bispecific antibody preclinical data presented at aacr annual meeting
-
6:05
context therapeutics announces encouraging initial ph 2 trial ona-xr metastatic breast cancer data
-
4:41
context therapeutics ceo says menarini collaboration may lead to better outcomes for cancer patients
-
1:01:15
key opinion leader webinar: context therapeutics
-
15:16
context therapeutics - collaborating to reshape women's cancer landscape
-
47:17
how to identify pro: context and relevant pro domains for cts
-
8:21
transforming female cancer treatments - martin lehr, ceo of context therapeutics